Colorectal Cancer Rates Show Surprising Rebound in New Study Data
A study in NEJM Evidence reveals a surprising 4 percent rebound in colorectal cancer rates for 2023, reversing decades of decline. Researchers highlight unexplained rising trends among regularly screened older adults.
For two decades, the fight against colorectal cancer stood out as one of preventive medicine's greatest success stories. Driven by routine screening and heightened awareness, incidence rates steadily plunged by roughly one-third. However, alarming data recently published in the journal NEJM Evidence reveal a surprising reversal, prompting deep concern among physicians and researchers.
Following years of decline—moving from 55 cases per 100,000 individuals down to a low of 36—2023 saw a sharp rebound to 38 cases per 100,000 people. This marks a 4 percent surge in just one year, observed uniformly across both men and women, and spanning both early and advanced stages of the disease. Researchers point to the 'birth year effect' as a leading hypothesis, suggesting that individuals born in the 1960s may face higher vulnerability due to environmental shifts or lifestyle changes.
Unexplained Rise Among Older Adults
One of the most troubling findings centers on adults aged 65 to 69. This age bracket experienced a rise in incidence despite roughly 80 percent of its members undergoing regular screenings. This data rules out delayed diagnoses stemming from pandemic-related backlogs, instead raising serious concerns over newly emerging biological or environmental risk factors.
Despite these mounting questions, health experts stress that screenings—primarily fecal occult blood tests and colonoscopies—remain the single most effective defense line. These examinations allow physicians to identify and remove precancerous polyps before malignancy develops. Alongside a balanced diet, physical activity, and avoiding smoking, authorities strongly urge the public to maintain regular follow-up screenings.
The Situation in Israel
According to the Israel Center for Disease Control, colorectal cancer ranks among the most prevalent malignancies locally, standing as the second most common cancer in women and the third in men, with roughly 2,500 to 2,800 new diagnoses annually. Incidence rates reach approximately 23.5 per 100,000 men and 18.1 per 100,000 women, with most cases diagnosed after age 50 and peaking past age 70.
Yet, alongside this broad footprint, recent decades have seen a consistent downward trend in domestic morbidity and mortality, largely fueled by the national screening program. These preventative measures have doubled early-stage diagnoses to about 40 percent, significantly boosting survival rates, even as experts monitor a separate upward tick among younger adults under 50.
